For a covered outpatient drug to be eligible for Federal Medicaid reimbursement, the manufacturer must enter into a rebate agreement administered by the Centers for Medicare & Medicaid Services (CMS) and pay quarterly rebates to the States. Previous OIG reviews found that States did not always bill and collect all rebates due for drugs administered by physicians to enrollees of Medicaid managed-care organizations (MCOs).
Wednesday, August 21, 2019
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
Component, if applicable:
Centers for Medicare & Medicaid Services
Type of Report: